CDF之声 | 武田制药总裁兼CEO卫博科：中国将成为全球医药创新的重要源头

“CDF之声”（CDF Voice）栏目旨在汇聚关注、支持和参与论坛的重要商业领袖，向国内公众和国际社会传递论坛与会代表心声。

过去的2021年，世纪疫情与国际变局持续交织，我国“两个一百年”奋斗目标历史交汇，中国与世界在激荡中复苏，企业和个人在磨砺中前行。

这一年，在中国，许多行业与企业迎接着全新的发展机遇和行业趋势；这一年，为中国，世界500强与行业领先企业的商业领袖们变中求新、变中求进，深耕中国，携手共进，共创未来。

今年的“CDF之声”栏目邀请参会代表分享过去一年来自己与所领导的企业、所在行业的经历以及他们的感悟。

今天做客“CDF之声”的是武田制药总裁兼CEO卫博科（Christophe Weber）。

卫博科指出，席卷全球的新冠肺炎疫情更加凸显出，拥有一个强有力的医疗保障体系，对于国家的经济健康和人民福祉至关重要。他认为中国就是一个很好的例证。

中国已经成为武田全球战略中更为重要的板块。他相信，随着中国大力激励创新，迈向更高质量的发展，中国将成为全球医药创新的重要源头之一。

展望后疫情时代，卫博科认为有三个重要的优先事项：

第一，保障医疗卫生投入和研发至关重要。

第二，我们必须共同努力，携手应对全球变暖，保护地球。

第三，新冠肺炎疫情让我们认识到国际合作的重要性和价值，国际间的合作对于建立创新生态系统也同样重要。

以下为中英文原文：

大家好！我谨代表武田制药，感谢中国发展高层论坛邀请我们参与此次重要的对话。

席卷全球的新冠肺炎疫情更加凸显出，拥有一个强有力的医疗保障体系，对于国家的经济健康和人民福祉至关重要。中国就是一个很好的例证。

事实上，中国一直在持续加大资金投入、持续提升创新药物可及性等举措，为强化医疗体系建设做出不懈努力。这些举措让武田倍感振奋，并希望以此为契机，为中国患者带来更多突破性的疗法。

中国的医疗卫生事业已经取得了卓有成效的进展。我想特别强调几个方面：

首先，中国的医疗卫生支出在GDP中所占的比重，已经从2019年的6.6%上升至2020年的7.1%，这一显著增长将会极大惠及患者。

其次，最新公布的国家医保目录纳入了更多创新疗法，以解决亟待满足的中国患者所需，其中也包括武田制药旗下2款罕见病药物阿加糖酶α注射用浓溶液和醋酸艾替班特注射液。

第三，在博鳌和大湾区开展的“先行先试”举措，有助于进一步践行中国政府“将人民群众的健康放在第一位”的承诺。

我们相信，中国将继续致力于为民众提供最好的药物。鉴于此，中国已经成为武田全球战略中更为重要的板块。

为了实现我们在中国的愿景，近期武田全球进行了战略性的组织架构调整，这将有助于我们加速实现为中国患者带来真正具有突破性的治疗方案的承诺。同时，我们也相信，大力激励创新，迈向更高质量的发展，将使中国在未来成为全球医药创新的重要源头之一。

由此，我也欣喜地和大家分享，我们正按计划推动“到2025年在中国上市超过15款新产品”的目标，并且有望提前在2024年实现。

展望后疫情时代，我认为有三个重要的优先事项：

第一，保障医疗卫生投入和研发至关重要。过去十年间，人类预期寿命延长、生活方式改变，针对复杂疾病出现了更为先进的治疗方案，这些都推动了医疗卫生领域的投资增长，并且其增速超过GDP和居民收入增速。近期的研发创新，推动了创新药物在许多领域取得了显著进展，但如果没有政府的支持，缺乏持续投入的医疗资金、药品定价背离了临床价值，这些有可能会阻碍创新的发展。

我们认为，以获得突破性创新疗法为导向的研发，其根本在于激励创新。而中国正通过政策引导、优化营商环境、扩大开放等举措营造更加优化的创新环境，尤其是在我们所处的医药行业。因此，我们也要共同努力，保护创新，在让患者获得更好的治疗的同时，提升医疗体系效率和提供以价值为基础的医疗服务。

第二，我们必须共同努力，携手应对全球变暖，保护地球。全球变暖有可能让登革热或寨卡这样的疾病在更大的范围内肆虐，我们要提前应对，不能等到真正发生时再予以关注。加强合作、加快临床开发并增加对全球传染病领域的投入，从而保护我们共同的生活环境免受疾病的肆虐和侵害。包括中国在内，每个人、每个国家都可以发挥作用。

最后，新冠肺炎疫情让我们认识到国际合作的重要性和价值。国际间合作对于建立创新生态系统将会一如既往的重要，让我们为未来可能要面对的流行性疾病做好准备，而医药行业在其中发挥着重要作用。

请允许我在此分享几个例子：建立一个全球范围、随时备用的医疗产品储备，如防护用品、医疗设备、检测装备、疫苗和治疗药物等；建立一个透明的全球预警系统，以便尽早发现疫情；以及投入研发资金，以更好地了解和预防人畜共患病，以及研发检测装备、疫苗和治疗药物来应对可能出现的病原体和疾病。

过去二十年间，中国发展高层论坛在加深国际社会对中国的了解以及促进合作方面发挥了重要作用。如今，中国的医药市场持续增长，医疗卫生现代化进程取得重要进展，今年中国发展高层论坛的举办可谓恰逢其时。

我期待学习中国在经济社会发展、创新生态构建等领域的宝贵经验。我也很高兴能与大家分享武田制药在全球、特别是在中国的发展规划，包括持续的创新研发、数据和数字化，提高药物可及性以及可持续发展等。

再次感谢！期待在中国发展高层论坛期间与大家进一步交流！

Hello, everyone! On behalf of Takeda, I would like to thank the China Development Forum for inviting us to be part of this important dialogue. 

The global COVID-19 pandemic has demonstrated that a strong healthcare system is essential to a country’s economic health and wellbeing. China is no exception.

In fact, China has been making a significant effort to elevate its healthcare system through increased funding and greater patient access to innovation. And that’s why we are excited about the opportunity for Takeda to bring more life-transforming treatments to people in China.

In this journey for China’s healthcare modernization, there has been impactful progress. I would like to highlight a few areas in particular:

First, China’s healthcare spend has increased from 6.6% of GDP in 2019 to 7.1% in 2020 – significant growth that will benefit patients.

Second, the recent NRDL update included more innovative therapies to address high unmet needs in China, including 2 rare disease therapies from Takeda – Replagel and Firazyr.

Finally, early access programs in Bo’Ao and the Greater Bay Area further reinforce China’s commitment to patient focused policies.

We believe that China will continue to build on its commitment to bringing the best medicine to its citizens and as such, China has become an even more important part of Takeda’s global strategy.

To support our vision for China, we recently evolved our global organization which we believe will help us accelerate our commitment to bringing truly life-transforming treatments to patients in China.  We also believe that China, if innovation is sufficiently rewarded, will become an important source of worldwide innovation in medicine in the future.

On that note, I am happy to announce that we are on track to launch more than 15 innovative drugs in China by 2024.

As we look ahead to our post-pandemic future, I see three important priorities:

First, it will be critical to protect healthcare financing and research. In the last decade, increasing life expectancy, lifestyle changes and the availability of more advanced solutions for complex diseases have driven investment in health care to rise faster than GDP and incomes. While recent innovation has led to dramatic advances in many areas of medicine, without support from governments, instability in healthcare financing and drug prices could impede this progress. 

We believe that rewarding innovation is fundamental to spurring research that leads to new, life-transforming treatments, and China has become increasingly favorable toward this, particularly in our industry. This is why we should work together to protect innovation while enabling better patient outcomes, including efforts to improve health care system efficiencies and value-based healthcare. 

Secondly, we must work together to make a concerted effort to address global warming and protect the planet. The reality of an increasingly warmer world means that we can’t afford to wait until a disease such as dengue or Zika become more widespread before we take notice. Greater collaboration, accelerated clinical development and increased investment in global infectious diseases will be required to protect our shared environment from diseases that will ravage the developing world and threaten new geographies. Everyone has a role to play in affecting change here, including China.

Finally, the COVID-19 pandemic has taught us the importance and value of international collaboration. This will continue to be critical in building an innovation ecosystem that can help prepare us for future pandemics and industry plays an important role in this. 

Let me share a few examples which include: Establishing a worldwide inventory and ready-to-use stock of protective equipment, medical devices, testing kits, vaccines and treatments; A transparent global detection system must be created to detect outbreaks early on; and funding research to better understand and prevent zoonotic diseases as well as the diagnostic kits, vaccines and treatments against possible emerging pathogens and diseases.

Over the past 20 years, the CDF has played a significant role in deepening the international community's understanding of China and opportunities for collaboration.Now with a growing pharmaceutical market and important progress being made to modernize healthcare in China, this year’s CDF event is particularly timely.

I look forward to learning about China's valuable experience in economic and social development, innovation ecology and other fields. I’m also excited to share Takeda's plans for continued innovation in research and development, data and digital, improving access to medicines and sustainable development both in our global efforts and in China specifically. 

Thank you again and I will speak with you more during this week’s discussions at CDF!

整理 - 佳琪

中国发展高层论坛由国务院发展研究中心主办，中国发展研究基金会承办，自2000年举办首届论坛以来，每年举办一次，已经连续举办22届。

中国发展高层论坛坚持“与世界对话，谋共同发展”的宗旨，形成了专业化、高层次的鲜明特色，是中国政府高层领导、全球商界领袖、国际组织和中外学者之间重要的对话平台。